Antibody–drug, peptide–drug, protein–drug, and oligo–drug conjugates with optimized linkers and oncology payloads — engineered with full analytics and documentation by Bio-Synthesis.
Bio-Synthesis designs and produces high-performance drug conjugates that link antibodies, peptides, proteins, and oligonucleotides to small-molecule and cytotoxic payloads. Our platform supports ADCs, peptide–drug conjugates (PDCs), protein–drug conjugates, and oligo–drug formats for oncology, immunology, and targeted delivery applications.
We provide end-to-end drug conjugation services — from carrier and linker strategy through conjugation, purification, analytics, and documentation — supporting both discovery and OEM/kit applications. The platform is optimized for controlled drug loading, minimal aggregation, and lot-to-lot reproducibility.
Antibody–drug, peptide–drug, protein–drug, and oligo–drug designs for targeted delivery, oncology, and immune modulation.
Drug–antibody and drug–peptide conjugates with fluorophores, chelators, or reporter tags for in vitro and in vivo imaging.
Method summaries, CoAs, and optional tech transfer packages to support preclinical, kit, and OEM programs.
Drug conjugation services can be combined with carrier delivery platforms (ADC & LNP) and broader bioconjugation services from Bio-Synthesis.
Antibody–Drug Conjugates (ADCs) combine monoclonal antibodies with potent cytotoxic or functional small-molecule payloads. Bio-Synthesis develops custom ADCs using cysteine, lysine, and site-directed conjugation strategies, optimizing linker choice, DAR, and aggregation for oncology and targeted delivery applications.
Oligonucleotide–Drug Conjugates (ODCs) combine siRNA, ASO, DNA/RNA, or aptamers with small-molecule payloads for targeted delivery, controlled activation, or dual-modality therapeutics. Bio-Synthesis supports aptamer–drug conjugates, siRNA–drug constructs, and other oligo–drug architectures.
Peptide–Drug Conjugates use targeting, cell-penetrating, or tumor-homing peptides to deliver small-molecule payloads to specific cells or tissues. Bio-Synthesis constructs PDCs with optimized linkers and spacers to balance potency, selectivity, and stability.
Protein–Drug Conjugates extend beyond antibodies to enzymes, receptor ectodomains, carrier proteins, and nanobodies. Bio-Synthesis develops protein–drug constructs that preserve biological function while delivering potent small molecules or reporters.
We work with antibodies, Fabs, nanobodies, peptides, proteins, enzymes, and oligonucleotides, including both standard and custom formats with appropriate conjugation handles.
In many cases we can source or synthesize carriers and certain payloads; in other cases, clients supply proprietary antibodies, peptides, proteins, or drugs. We will clarify material responsibilities during scoping.
Yes. We support projects that require enhanced documentation, lot statistics, and stability data suitable for diagnostic kits and OEM applications.
At minimum, we need the carrier identity, payload, desired conjugation type, intended application, and key performance metrics (e.g., potency, binding, imaging, PK) you plan to evaluate.
Share your oligo sequence format, carrier, application, and target performance. We will recommend a conjugation route, linker strategy, and QC package, then provide a project quote.
By submitting, you agree to be contacted regarding your request.
Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.